Influenza B Florida

Influenza-B Virus Florida 04/06
Cat. No.
BT27247
Source
Synonyms
Appearance
Sterile Filtered colorless solution.
Purity
Greater than 90.0% as determined byAnalysis by SDS-PAGE.
Usage

THE BioTek's products are furnished forLABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Shipped with Ice Packs
In Stock

Description

Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza B virus, strain B/Florida/04/06. The Influenza B Virus was purified by Ultracentrifugation with 10-40 % sucrose gradient.

Product Specs

Introduction
Influenza B virus, a member of the Orthomyxoviridae family, exclusively infects humans and seals. Unlike Influenza A virus, which affects a broader range of hosts, Influenza B's mutation rate sits between that of Influenza A and C viruses. Although it evolves slower than Influenza A, its mutation rate still hinders the development of long-lasting immunity. Structurally, the virus comprises a matrix protein, envelope, nucleoprotein complex, nucleocapsid, and polymerase complex. Its spherical or filamentous form features approximately 500 surface projections composed of hemagglutinin and neuraminidase. The genome of the Influenza B virus is 14,648 nucleotides long, segmented into eight linear negative-sense, single-stranded RNA strands. Each segment is enclosed within a separate nucleocapsid, and these nucleocapsids are further enveloped by a single outer membrane.
Description
This product consists of allantoic fluid harvested from 10-day-old embryonated eggs infected with the Influenza B virus strain B/Florida/04/06. The virus was purified using ultracentrifugation with a 10-40% sucrose gradient.
Inactivation
This product has been treated with thimerosal and beta-propiolactone to inactivate the virus. Standard laboratory practices for safe handling of microbiological and viral agents are required during use.
Physical Appearance
This product appears as a sterile-filtered, colorless solution.
Formulation
The B/Florida/04/06 solution is formulated in STE buffer containing 0.1% sodium azide (NaN3) and 0.005% thimerosal.
Stability
For optimal stability, B/Florida/04/06 should be stored below -18°C. While it can remain stable at 4°C for up to 4 weeks, repeated freezing and thawing should be avoided.
Purity
Analysis by SDS-PAGE has determined a purity of greater than 90.0%.
Immunological Activity
Serological studies of influenza B virus, immunogen for antibody production.Tested with anti-influenza B monoclonal antibodies in ELISA.

Product Science Overview

Introduction

Influenza B virus is a member of the Orthomyxoviridae family, which also includes Influenza A and C viruses. Unlike Influenza A, which infects multiple species, Influenza B primarily infects humans and seals. The strain Influenza B/Florida/04/2006 (B/Florida/04/06) was first isolated in Florida, USA, in 2006 .

Genetic and Structural Characteristics

The Influenza B virus has a segmented genome consisting of eight segments of linear negative-sense, single-stranded RNA. Each segment is encapsidated in a separate nucleocapsid, and the nucleocapsids are surrounded by an envelope. The virus is approximately 14,648 nucleotides long .

The surface of the Influenza B virus is covered with approximately 500 projections made of two glycoproteins: hemagglutinin (HA) and neuraminidase (NA). These proteins are crucial for the virus’s ability to infect host cells and for the release of new viral particles .

Evolution and Mutation

Influenza B viruses evolve more slowly than Influenza A viruses but faster than Influenza C viruses. The mutation rate of Influenza B is about 2-3 times lower than that of Influenza A. Despite this slower mutation rate, Influenza B still mutates enough to prevent lasting immunity, necessitating annual updates to the influenza vaccine .

Isolation and Purification

The B/Florida/04/06 strain was isolated from allantoic fluid of 10-day-old embryonated eggs inoculated with the virus. The virus was then purified using ultracentrifugation with a 10-40% sucrose gradient. Inactivation of the virus was achieved using thimerosal and beta-propiolactone treatment .

Immunological Activity

The B/Florida/04/06 strain has been used in serological studies and as an immunogen for antibody production. It has been tested with anti-influenza B monoclonal antibodies in ELISA assays, demonstrating its utility in research and vaccine development .

Applications and Reagents

Various reagents have been developed from the B/Florida/04/06 strain, including proteins and antibodies. These reagents are used in laboratory research to study the virus’s structure, function, and immunogenic properties. For example, hemagglutinin (HA) and nucleoprotein (NP) proteins from this strain are commonly used in research .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.